Bevatas (bevacizumab biosimilar) / Intas - LARVOL DELTA

A promise of nose to brain delivery of bevacizumab intranasal sol-gel formulation substantiated in rat C6 glioma model. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Further pharmacokinetic studies revealed that the optimized intranasal bevacizumab formulation achieved a significantly higher brain concentration Cmax = 147.9 ng/ml, indicating improved bioavailability compared to rats administered with intravenous bevacizumab formulation (BEVATAS®), which had a Cmax of 127.2 ng/ml...Furthermore, the success of this delivery method could open new avenues for treating other neurological disorders, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke. By providing effective brain-targeted therapies, this approach has the potential to revolutionize treatment options and improve outcomes for a broad spectrum of neurological conditions."

Journal • Preclinical • Alzheimer's Disease • Brain Cancer • Cardiovascular • CNS Disorders • CNS Tumor • Glioblastoma • Glioma • Movement Disorders • Multiple Sclerosis • Oncology • Parkinson's Disease • Solid Tumor

Efficacy and Safety of an Indian Bevacizumab BIOSimilar (BEVATAS) for Retinal Vein Occlusion (BIOS-RVO Study). (PubMed, Clin Ophthalmol) - "The BIOS-RVO study demonstrates that Bevatas is an effective and safe treatment option for both CRVO and BRVO. These findings support the use of Bevatas as a cost-effective alternative to branded anti-VEGF agents, particularly in resource-limited settings."

Journal • Retinal Disorders • Retinal Vein Occlusion

Efficacy of an Indian Bevacizumab BIOSimilar (BEVATAS) for Type 1 and Aggressive Posterior Retinopathy of Prematurity (BIOS-ROP Study). (PubMed, Clin Ophthalmol) - "Low-cost biosimilars can help sustain healthcare systems in lower-middle income countries (LMICs) with escalating healthcare expenditures. They can also improve healthcare equity by making vision-saving therapies like bevacizumab more affordable and accessible."

Journal • Retinal Disorders • Retinopathy of Prematurity

A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men. (PubMed, Cancer Chemother Pharmacol) - "This study demonstrated PK bioequivalence of INTP24 to US-bevacizumab and EU-bevacizumab in healthy male subjects and showed similar safety and immunogenicity profiles across the treatment groups."

Clinical • Journal • PK/PD data • Herpes Zoster • Varicella Zoster

The trough levels of bevacizumab significantly affect the outcome of the treatment in patients with metastatic colorectal cancer: A Turkish Oncology Group study. (ASCO 2018) - " Eighty-eight patients with mCRC treated with Beva plus either irinotecan or oxaliplatin-based regimens were prospectively included. In conclusion, our results show that the pretreatment angiogenic factor levels are not predictors of outcomes for Beva plus chemotherapy in mCRC patients. The development of anti-Beva Abs seems has no effect on the efficacy of the Beva treatment. The trough levels of Beva at the first cycle could be a good predictor of survival for Beva treatment in patients with mCRC."

Clinical • Colorectal Cancer

Intas launches biosimilar bevacizumab with aggressive pricing (The Economic Times) - "Ahmedabad based Intas pharma has launched the biosimilar drug Bevacizumab in India used for treating several types of cancer including colorectal, lung and cervical cancer besides certain form of brain tumours....it will launch the drug at Rs 39,995 for 400mg, which is 60% lower than the currently available treatment option."

Biosimilar launch • Pricing • Biosimilar

Bevetex Vs Bevatas: Delhi HC junks Sun Pharma arm plea against Intas Pharma over trademark (Business Medical Dialogues) - "In a major setback to drug giant Sun Pharmaceuticals Ltd.'s arm, Sun Pharma Laboratories Ltd., the Delhi high court has recently dismissed a petition filed by the company related to the alleged violation of the trademark of its cancer drug. Sun pharma had knocked on the doors of the high court challenging the order by a trial court that dismissed its plea against Intas Pharmaceutical. The plea sought to direct to restrict the sale of allegedly infringed trademark 'BEVATAS' by Intas Pharma that is deceptively similar to that of Sun Pharma's trademark 'BEVETEX'."

Corporate lawsuit